| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 2, 2025 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 2, 2025 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2025 | Buy | Lake Street | |
| 12/17/2024 | $10.00 | Overweight | Cantor Fitzgerald |
| 11/11/2024 | $11.00 | Buy | ROTH MKM |
| 10/25/2024 | $12.50 | Outperform | Northland Capital |
| 9/16/2024 | $10.00 | Outperform | Oppenheimer |
| 5/30/2024 | $12.00 | Buy | Canaccord Genuity |
Lake Street initiated coverage of TriSalus Life Sciences with a rating of Buy
Cantor Fitzgerald initiated coverage of TriSalus Life Sciences with a rating of Overweight and set a new price target of $10.00
ROTH MKM initiated coverage of TriSalus Life Sciences with a rating of Buy and set a new price target of $11.00
Funding Anticipated to Accelerate Applications Already in Use and New Additional Potential Applications Anticipated Preferred Stock Exchange to Simplify Capital Structure Private Placement Expected to Fund Business to Profitability Healthcare Focused Long-term Investors Support Strategic Vision TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and techn
Revenues of $8.3 Million in Q4 and $29.4 Million for Full-Year 2024, Representing Growth of 44% And 59%, Respectively, Versus the Prior Year Periods Gross Margin of 85% and 86% for Q4 and Full-Year 2024 Reaffirmed 2025 Guidance of Greater than 50% Revenue Growth, Greater than 20% Reduction in Operating Expenses, Positive EBITDA, and Positive Cash flow in H2 2025 Management to host earnings conference call on March 27 at 8:00 a.m. EDT TriSalus Life Sciences Inc., (NASDAQ:TLSI), oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our inv
TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that the Centers for Medicare & Medicaid Services (CMS) has established a new Level II HCPCS code for the TriNav® Infusion System, effective April 1, 2025. This new code, C8004, provides reimbursement clarity for simulation angiograms—commonly known as mapping procedures—conducted prior to transarterial radioembolization (TARE). The introduction of C8004 provides validation of TriNav's growing role in pre-treatment ma
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
D - TriSalus Life Sciences, Inc. (0001826667) (Filer)
EFFECT - TriSalus Life Sciences, Inc. (0001826667) (Filer)
DEF 14A - TriSalus Life Sciences, Inc. (0001826667) (Filer)
HealthCare Industry Veterans William Valle and Gary Gordon, M.D. add Strategic Expertise in Medical Devices, Reimbursement, and Pancreatic Cancers TriSalus Life Sciences® Inc. (NASDAQ:TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced the appointment of two distinguished HealthCare Industry veterans to its Board of Directors. Mr. William J. Valle and Gary B. Gordon, M.D., Ph.D., joined the Company's Board of Directors, effective as of January 29, 2025. "We are thrilled to welcome William Valle and Dr. Ga
James Young Appointed Chief Financial Officer, Richard Marshak Appointed Chief Commercial Officer, Jodi Devlin Appointed Chief of Clinical Strategy and Operations TriSalus Life Sciences, Inc., (NASDAQ:TLSI), an oncology company dedicated to improving outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and our investigational immunotherapy, today announced key updates to its executive leadership team. James (Jim) Young, who previously served as the Company's Senior Vice President of Investor Relations and Treasurer, has been appointed as the Company's Chief Financial Officer. In this role, Mr. Young succeeds Sean Murp
TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, has announced the addition of Riad Salem, M.D., to its Scientific Advisory Board (SAB). Dr. Salem is the Chief of Interventional Radiology, and a Professor of Radiology, Surgery, and Medicine in Chicago. Mary Szela, Chief Executive Officer and President of TriSalus, stated, "We are thrilled to welcome Dr. Salem to our SAB. His pioneering work in radiological research and leadership in developing innovative treatments for liver cancer and other
Revenues of $8.3 Million in Q4 and $29.4 Million for Full-Year 2024, Representing Growth of 44% And 59%, Respectively, Versus the Prior Year Periods Gross Margin of 85% and 86% for Q4 and Full-Year 2024 Reaffirmed 2025 Guidance of Greater than 50% Revenue Growth, Greater than 20% Reduction in Operating Expenses, Positive EBITDA, and Positive Cash flow in H2 2025 Management to host earnings conference call on March 27 at 8:00 a.m. EDT TriSalus Life Sciences Inc., (NASDAQ:TLSI), oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our inv
Q4 Revenue of approximately $8.3 million represents approximately 44% growth versus Q4 2023 Full year 2024 Revenue of approximately $29.4 million represent approximately 59% growth versus full year 2023 Q4 Operating Cash Flow of approximately ($5.6) million is a notable improvement compared to ($10.8) million in Q3 Company expects to achieve positive full year EBITDA in 2025 and positive Cash Flow during the second half of 2025 Call Scheduled for Thursday, March 27, 2025, at 8:00 a.m. ET TriSalus Life Sciences® Inc. (NASDAQ:TLSI), is announcing preliminary unaudited fourth quarter and full year 2024 financial results and details of the upcoming conference call. Preliminary
– Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year – Provided 2025 guidance with expectations of over 50% annual sales growth, 20%+ reduction in operating expenses, positive full-year EBITDA, and positive cash flow in H2 2025 – Launched TriNav® LV Infusion System and TriGuide™ Guiding Catheter for larger vessels and complex cases, expanding the TriNav system's full access to the $375 million embolization market – Initiated the PROTECT registry trial using the TriNav system to treat multinodular goiters, expanding the TriNav system's reach into the $400 million thyroid embolization market – Presented positive Phase 1 da
SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)